Literature DB >> 17523756

Building bridges between academic research and policy formulation: when costing less means costing more.

Amiram Gafni, Stephen Birch.   

Abstract

Mesh:

Year:  2007        PMID: 17523756     DOI: 10.2165/00019053-200725060-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  11 in total

1.  Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

Authors:  Andreas Laupacis
Journal:  CMAJ       Date:  2002-01-08       Impact factor: 8.262

2.  Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?

Authors:  Amiram Gafni; Stephen Birch
Journal:  CMAJ       Date:  2003-04-01       Impact factor: 8.262

3.  NICE methodological guidelines and decision making in the National Health Service in England and Wales.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1993-12       Impact factor: 3.883

Review 5.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

6.  The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold.

Authors:  Stephen Birch; Amiram Gafni
Journal:  J Health Serv Res Policy       Date:  2006-01

Review 7.  Building bridges between academic research and policy formulation: the PRUFE framework - an integral part of Ontario's evidence-based HTPA process.

Authors:  Ron Goeree; Leslie Levin
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.

Authors:  A Gafni; S Birch
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

9.  Cost-effectiveness analysis: are the outputs worth the inputs?

Authors:  D Naylor
Journal:  ACP J Club       Date:  1996 Jan-Feb

10.  Economic evaluation of sirolimus-eluting stents.

Authors:  Fiona M Shrive; Braden J Manns; P Diane Galbraith; Merril L Knudtson; William A Ghali
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

View more
  1 in total

Review 1.  Generic and therapeutic substitutions: are they always ethical in their own terms?

Authors:  Mubarak AlAmeri; Miran Epstein; Atholl Johnston
Journal:  Pharm World Sci       Date:  2010-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.